Sphingosine Kinases at the Intersection of Pro-Inflammatory LPS and Anti-Inflammatory Endocannabinoid Signaling in BV2 Mouse Microglia Cells

Microglia, the resident immune cells of the central nervous system, play important roles in brain homeostasis as well as in neuroinflammation, neurodegeneration, neurovascular diseases, and traumatic brain injury. In this context, components of the endocannabinoid (eCB) system have been shown to shift microglia towards an anti-inflammatory activation state. Instead, much less is known about the functional role of the sphingosine kinase (SphK)/sphingosine-1-phosphate (S1P) system in microglia biology. In the present study, we addressed potential crosstalk of the eCB and the S1P systems in BV2 mouse microglia cells challenged with lipopolysaccharide (LPS). We show that URB597, the selective inhibitor of fatty acid amide hydrolase (FAAH)—the main degradative enzyme of the eCB anandamide—prevented LPS-induced production of tumor necrosis factor-α (TNFα) and interleukin-1β (IL-1β), and caused the accumulation of anandamide itself and eCB-like molecules such as oleic acid and cis-vaccenic acid ethanolamide, palmitoylethanolamide, and docosahexaenoyl ethanolamide. Furthermore, treatment with JWH133, a selective agonist of the eCB-binding cannabinoid 2 (CB2) receptor, mimicked the anti-inflammatory effects of URB597. Interestingly, LPS induced transcription of both SphK1 and SphK2, and the selective inhibitors of SphK1 (SLP7111228) and SphK2 (SLM6031434) strongly reduced LPS-induced TNFα and IL-1β production. Thus, the two SphKs were pro-inflammatory in BV2 cells in a non-redundant manner. Most importantly, the inhibition of FAAH by URB597, as well as the activation of CB2 by JWH133, prevented LPS-stimulated transcription of SphK1 and SphK2. These results present SphK1 and SphK2 at the intersection of pro-inflammatory LPS and anti-inflammatory eCB signaling, and suggest the further development of inhibitors of FAAH or SphKs for the treatment of neuroinflammatory diseases.

[1]  D. Thomas,et al.  Pre-analytical sample handling standardization for reliable measurement of metabolites and lipids in LC-MS-based clinical research , 2023, Journal of mass spectrometry and advances in the clinical lab.

[2]  M. Gräler,et al.  The Impact of Sphingosine Kinases on Inflammation-Induced Cytokine Release and Vascular Endothelial Barrier Integrity , 2022, International journal of molecular sciences.

[3]  P. Bruni,et al.  The TRPV1 Receptor Is Up-Regulated by Sphingosine 1-Phosphate and Is Implicated in the Anandamide-Dependent Regulation of Mitochondrial Activity in C2C12 Myoblasts , 2022, International journal of molecular sciences.

[4]  E. Denovan‐Wright,et al.  The microglial endocannabinoid system is similarly regulated by lipopolysaccharide and interferon gamma , 2022, Journal of Neuroimmunology.

[5]  E. Carreira,et al.  Cannabinoid CB2 Receptors Modulate Microglia Function and Amyloid Dynamics in a Mouse Model of Alzheimer’s Disease , 2022, Frontiers in Pharmacology.

[6]  M. Maccarrone,et al.  Microglial Endocannabinoid Signalling in AD , 2022, Cells.

[7]  E. Denovan‐Wright,et al.  The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation , 2022, Frontiers in Pharmacology.

[8]  B. Peng,et al.  TRPV1 channel mediates NLRP3 inflammasome-dependent neuroinflammation in microglia , 2021, Cell Death & Disease.

[9]  F. Schumacher,et al.  Mouse Liver Compensates Loss of Sgpl1 by Secretion of Sphingolipids into Blood and Bile , 2021, International journal of molecular sciences.

[10]  M. Maccarrone,et al.  Role of Specialized Pro-Resolving Mediators in Neuropathic Pain , 2021, Frontiers in Pharmacology.

[11]  T. Bisogno,et al.  Fatty Acid Amide Hydrolase (FAAH) Inhibition Modulates Amyloid-Beta-Induced Microglia Polarization , 2021, International journal of molecular sciences.

[12]  J. Chun,et al.  Lysophospholipid (S1P) receptors in GtoPdb v.2021.2 , 2021, IUPHAR/BPS Guide to Pharmacology CITE.

[13]  Jeffrey A. Cohen,et al.  Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions , 2021, The Lancet.

[14]  P. Rao,et al.  Cannabinoid-induced changes in the immune system: The role of microRNAs. , 2021, International immunopharmacology.

[15]  E. Sturm,et al.  Neuroprotective and Immunomodulatory Action of the Endocannabinoid System under Neuroinflammation , 2021, International journal of molecular sciences.

[16]  L. McCullough,et al.  The Functional Role of Sphingosine Kinase 2 , 2021, Frontiers in Molecular Biosciences.

[17]  P. Clayton,et al.  Palmitoylethanolamide: A Natural Compound for Health Management , 2021, International journal of molecular sciences.

[18]  Samuel S. Duffy,et al.  The cannabinoid system and microglia in health and disease , 2021, Neuropharmacology.

[19]  S. Spiegel,et al.  Deletion or inhibition of SphK1 mitigates fulminant hepatic failure by suppressing TNFα‐dependent inflammation and apoptosis , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  A. Torsello,et al.  Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective Effects , 2021, International journal of molecular sciences.

[21]  P. Edison,et al.  Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? , 2020, Nature Reviews Neurology.

[22]  Y. Hannun,et al.  Transcriptional Regulation of Sphingosine Kinase 1 , 2020, Cells.

[23]  Justin L. Black,et al.  Dissecting Gq/11-Mediated Plasma Membrane Translocation of Sphingosine Kinase-1 , 2020, Cells.

[24]  J. Pfeilschifter,et al.  The S1P–S1PR Axis in Neurological Disorders—Insights into Current and Future Therapeutic Perspectives , 2020, Cells.

[25]  B. Barboni,et al.  Advances in the discovery of fatty acid amide hydrolase inhibitors: what does the future hold? , 2020, Expert opinion on drug discovery.

[26]  Yumin Zhang,et al.  Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology , 2020, Frontiers in Neurology.

[27]  T. Bisogno,et al.  Cannabinoids and the expanded endocannabinoid system in neurological disorders , 2019, Nature Reviews Neurology.

[28]  A. Petcherski,et al.  Sphingosine kinase 2 is a negative regulator of inflammatory macrophage activation. , 2019, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[29]  S. Sonnino,et al.  Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases , 2019, Front. Pharmacol..

[30]  B. Brüne,et al.  Sphingosine-1-Phosphate and Macrophage Biology—How the Sphinx Tames the Big Eater , 2019, Front. Immunol..

[31]  G. van Echten-Deckert,et al.  Neural sphingosine 1‐phosphate accumulation activates microglia and links impaired autophagy and inflammation , 2019, Glia.

[32]  D. Friedman,et al.  Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders , 2019, The Lancet Neurology.

[33]  Yumin Zhang,et al.  Anti-Inflammatory Effects by Pharmacological Inhibition or Knockdown of Fatty Acid Amide Hydrolase in BV2 Microglial Cells , 2019, Cells.

[34]  T. Hla,et al.  Sphingosine 1-phosphate and inflammation. , 2019, International immunology.

[35]  P. Morales,et al.  Cannabinoid Ligands Targeting TRP Channels , 2019, Front. Mol. Neurosci..

[36]  M. Ballantyne,et al.  Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse , 2019, European journal of pharmacology.

[37]  Eun-Kyoung Kim,et al.  TLR4 (toll-like receptor 4) activation suppresses autophagy through inhibition of FOXO3 and impairs phagocytic capacity of microglia , 2018, Autophagy.

[38]  T. Uyama,et al.  Endocannabinoids and related N-acylethanolamines: biological activities and metabolism , 2018, Inflammation and regeneration.

[39]  S. Hickman,et al.  Microglia in neurodegeneration , 2018, Nature Neuroscience.

[40]  A. Huwiler,et al.  The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. , 2017, Pharmacology & therapeutics.

[41]  G. van Echten-Deckert,et al.  Sphingosine 1-phosphate - A double edged sword in the brain. , 2017, Biochimica et biophysica acta. Biomembranes.

[42]  M. Maccarrone Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years , 2017, Front. Mol. Neurosci..

[43]  M. Colonna,et al.  Microglia Function in the Central Nervous System During Health and Neurodegeneration. , 2017, Annual review of immunology.

[44]  H. de Vries,et al.  Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity , 2017, Nature Communications.

[45]  Huazhen Chen,et al.  N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling , 2016, Journal of Neuroinflammation.

[46]  Tobias Hoch,et al.  Identification of the oleic acid ethanolamide (OEA) isomer cis-vaccenic acid ethanolamide (VEA) as a highly abundant 18:1 fatty acid ethanolamide in blood plasma from rats and humans , 2016, Analytical and Bioanalytical Chemistry.

[47]  S. O'Sullivan,et al.  An update on PPAR activation by cannabinoids , 2016, British journal of pharmacology.

[48]  N. Quan,et al.  Neuroinflammation: the devil is in the details , 2016, Journal of neurochemistry.

[49]  K. Mackie,et al.  An Introduction to the Endogenous Cannabinoid System , 2016, Biological Psychiatry.

[50]  Dayong Zhang,et al.  Sphingosine kinase 1/sphingosine-1-phosphate regulates the expression of interleukin-17A in activated microglia in cerebral ischemia/reperfusion , 2016, Inflammation Research.

[51]  Jian Cheng,et al.  Sphingosine kinase 1 mediates neuroinflammation following cerebral ischemia , 2015, Experimental Neurology.

[52]  Ainoa Rueda-Zubiaurre,et al.  Endocannabinoids drive the acquisition of an alternative phenotype in microglia , 2015, Brain, Behavior, and Immunity.

[53]  W. Santos,et al.  Sphingosine Kinase 2 Inhibition and Blood Sphingosine 1-Phosphate Levels , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[54]  B. Przewłocka,et al.  Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures , 2015, Neural plasticity.

[55]  J. Leza,et al.  Systemic Administration of Oleoylethanolamide Protects from Neuroinflammation and Anhedonia Induced by LPS in Rats , 2015, The international journal of neuropsychopharmacology.

[56]  W. Santos,et al.  Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. , 2015, Journal of medicinal chemistry.

[57]  M. O’Banion,et al.  Neuroinflammation and M2 microglia: the good, the bad, and the inflamed , 2014, Journal of Neuroinflammation.

[58]  R. Proia,et al.  Sphingosine Kinases Are Not Required for Inflammatory Responses in Macrophages* , 2013, The Journal of Biological Chemistry.

[59]  P. Gressens,et al.  Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro , 2013, Brain, Behavior, and Immunity.

[60]  C. Compagnucci,et al.  Type-1 (CB1) Cannabinoid Receptor Promotes Neuronal Differentiation and Maturation of Neural Stem Cells , 2013, PloS one.

[61]  M. Pistis,et al.  Anandamide and 2-arachidonoylglycerol: Pharmacological Properties, Functional Features, and Emerging Specificities of the Two Major Endocannabinoids , 2012, Molecular Neurobiology.

[62]  P. Chameau,et al.  Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors , 2012, Proceedings of the National Academy of Sciences.

[63]  C. Usai,et al.  The endocannabinoid system in rat gliosomes and its role in the modulation of glutamate release , 2011, Cellular and Molecular Life Sciences.

[64]  B. Wattenberg Role of sphingosine kinase localization in sphingolipid signaling. , 2010, World journal of biological chemistry.

[65]  F. Ginhoux,et al.  Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages , 2010, Science.

[66]  S. Pyne,et al.  Interaction between anandamide and sphingosine‐1‐phosphate in mediating vasorelaxation in rat coronary artery , 2010, British journal of pharmacology.

[67]  M. Cascio,et al.  Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. , 2010, Carcinogenesis.

[68]  Peter Natesan Pushparaj,et al.  Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia , 2010, Neuroscience.

[69]  A. Spagnolo,et al.  Anandamide enhances IL‐10 production in activated microglia by targeting CB2 receptors: Roles of ERK1/2, JNK, and NF‐κB , 2010, Glia.

[70]  K. Jakobs,et al.  Galpha(q)-mediated plasma membrane translocation of sphingosine kinase-1 and cross-activation of S1P receptors. , 2009, Biochimica et biophysica acta.

[71]  R. P. Landry,et al.  Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation , 2009, Molecular pain.

[72]  D. Im,et al.  Characterization of N,N,-dimethyl-D-erythro-sphingosine-induced apoptosis and signaling in U937 cells: independence of sphingosine kinase inhibition. , 2008, Prostaglandins & other lipid mediators.

[73]  L. Obeid,et al.  Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages. , 2008, Prostaglandins & other lipid mediators.

[74]  J. Whitaker,et al.  Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators , 2007, FEBS letters.

[75]  P. Chomczyński,et al.  The single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction: twenty-something years on , 2006, Nature Protocols.

[76]  J. Pfeilschifter,et al.  Histamine increases sphingosine kinase-1 expression and activity in the human arterial endothelial cell line EA.hy 926 by a PKC-alpha-dependent mechanism. , 2006, Biochimica et biophysica acta.

[77]  Daniele Piomelli,et al.  Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). , 2006, CNS drug reviews.

[78]  Yun Bai,et al.  Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation , 2005, Journal of Neuroinflammation.

[79]  Y. Igarashi,et al.  Identification of functional nuclear export sequences in human sphingosine kinase 1. , 2003, Biochemical and biophysical research communications.

[80]  A. Finazzi-Agro’,et al.  Cannabimimetic Activity, Binding, and Degradation of Stearoylethanolamide within the Mouse Central Nervous System , 2002, Molecular and Cellular Neuroscience.

[81]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[82]  Z. Vogel,et al.  Anandamide may mediate sleep induction , 1997, Nature.

[83]  J. Pfeilschifter,et al.  Pharmacology of the sphingosine-1-phosphate signalling system. , 2013, Handbook of experimental pharmacology.

[84]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .